SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) and Sono Bello announced today that they had reached an agreement to begin offering the novel Obalon Balloon System for non-surgical weight loss in Sono Bello centers across the country. The Obalon Balloon System will be the exclusive non-invasive weight loss technology offered in Sono Bello centers.
“We are thrilled to be partnering with Sono Bello to make the Obalon Balloon System more widely accessible to patients seeking a scientifically-proven, FDA-approved weight loss solution," said Andy Rasdal, Chief Executive Officer of Obalon. "Our desire to partner with Sono Bello is fueled by their strong commitment to safety, clinical quality, and a proven track record of patient satisfaction, all of which are critical to developing a new technology and therapy. Of course, Sono Bello’s marketing prowess in directly reaching patients is also very attractive to us.”
Sono Bello is the largest cosmetic surgery group practice in the U.S., with over 40 locations and 100+ board-certified plastic surgeons who have performed more than 100,000 face and body procedures. Obalon Therapeutics developed the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled balloon for non-surgical weight loss, and currently offers the Obalon Balloon to bariatric surgeons, gastroenterologists and plastic surgeons.
“At Sono Bello, we are committed to providing our patients with the best options for whole body transformations, and have been looking to add a weight loss treatment that meets our high clinical and safety standards for some time,” said Chris Par, Chief Executive Officer of Sono Bello. “Offering the Obalon Balloon System to our patients provides us the ability to meet the increasing demand for non-surgical solutions that will positively impact the lives of people who struggle with weight loss. We intend to begin offering the Obalon Balloon System in multiple centers in the fourth quarter of 2017.”
The Obalon Balloon treatments will be performed by board certified physicians, a requirement of the highest standard of care within Sono Bello. During the six-month treatment regimen, patients will also participate in a professionally supervised nutrition and exercise program to help change their habits and optimize weight loss results.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
About Sono Bello
Sono Bello, a Seattle based company founded in 2008, has the largest private group practice of experienced plastic surgeons with over 100 board certified physicians and 40 locations in the U.S. Sono Bello’s team of highly skilled physicians specializes exclusively in facial and body cosmetic procedures and is focused on providing cutting-edge, personalized total body transformations for its clients. Sono Bello believes facial and body cosmetic procedures to be both an art and a science. Over the years, Sono Bello has seen that when the two work together seamlessly, lives are changed for the better. For more information, please visit www.sonobello.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits of the Obalon’s product. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Obalon believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements. Forward-looking statements are subject to risks and uncertainties that may cause Obalon’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the anticipated adoption of the Obalon balloon system by members of the Sono Bello practice group and its patients; the company’s ability to achieve or sustain profitability; the company’s ability to predict its future prospects and forecast its financial performance and growth; the rate at which physicians and patients adopt and use the company’s balloon system; the effect of adverse events or other negative developments involving other companies’ intragastric balloons or other obesity treatments; the company’s ability to educate physicians on safe and proper use of the Obalon balloon system; the rate at which patients may experience serious adverse device events as the result of the misuse or malfunction of, or design flaws in, the company’s products; the company’s ability to obtain FDA approval or other regulatory approvals for its future products and product improvements; the company’s ability to adequately protect its proprietary technology and maintain its issued patents and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com
Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 1565
mdriscoll@evolvemkd.com